Sugi Predict

Sugi Predict / Compounds / SCHEMBL25752675

SCHEMBL25752675

SCHEMBL25752675

Cn1cc(NC(=O)OC(C)(C)C)c2c(=O)n(CCOCc3ccccc3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 2/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ CTSS P25774 1/20 0.39
▸ P2RX7 Q99572 1/20 0.39
▸ L3MBTL1 Q9Y468 4/20 0.38
▸ PPARG P37231 1/20 0.37
▸ BRD4 O60885 1/20 0.37
▸ RAB9A P51151 2/20 0.35
▸ SYK P43405 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ MET P08581 1/20 0.34
▸ AXL P30530 1/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27199304 0.89 L3MBTL1 (0.39) CNR2L3MBTL1RAB9AMETAXL
SCHEMBL25752652 0.86 CNR2 (0.39) CNR2P2RX7RAB9ANPC1
SCHEMBL25670769 0.82 CNR2 (0.42) CNR2P2RX7PPARGBRD4
SCHEMBL30895065 0.79 CNR2 (0.38) CNR2P2RX7RAB9ANPC1
SCHEMBL25670291 0.78 CNR2 (0.39) CNR2P2RX7BRD4
SCHEMBL30895101 0.77 DRD2 (0.38) CNR2
SCHEMBL25752777 0.77 CNR2 (0.39) CNR2L3MBTL1BRD4CA12CA1
SCHEMBL25752676 0.76 MAPK14 (0.36) BRD4
SCHEMBL27199319 0.76 TP53 (0.39) CNR2RAB9ANPC1
Trifluoroacetic Acid SCHEMBL27199483 0.76 MEN1 (0.34) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 PPARA 3491/4885CNR2 3169/4885CTSS 3957/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 PPARA 3491/4885CNR2 3169/4885CTSS 3957/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 PPARA 3491/4885CNR2 3169/4885CTSS 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.